GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » E10
中文

Agenus (Agenus) E10

: $-23.09 (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Agenus's adjusted earnings per share data for the three months ended in Dec. 2023 was $-2.400. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-23.09 for the trailing ten years ended in Dec. 2023.

During the past 5 years, the average E10 Growth Rate was 2.70% per year. During the past 10 years, the average E10 Growth Rate was 12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Agenus was 24.80% per year. The lowest was 0.20% per year. And the median was 18.50% per year.

As of today (2024-04-23), Agenus's current stock price is $6.9505. Agenus's E10 for the quarter that ended in Dec. 2023 was $-23.09. Agenus's Shiller PE Ratio of today is .


Agenus E10 Historical Data

The historical data trend for Agenus's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.05 -23.06 -22.14 -23.90 -23.09

Agenus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.90 -23.84 -23.45 -23.35 -23.09

Competitive Comparison

For the Biotechnology subindustry, Agenus's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Agenus's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's Shiller PE Ratio falls into.



Agenus E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agenus's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.4/129.4194*129.4194
=-2.400

Current CPI (Dec. 2023) = 129.4194.

Agenus Quarterly Data

per share eps CPI Adj_EPS
201403 -0.200 99.695 -0.260
201406 -2.600 100.560 -3.346
201409 -2.600 100.428 -3.351
201412 -8.200 99.070 -10.712
201503 -5.600 99.621 -7.275
201506 -10.600 100.684 -13.625
201509 -3.200 100.392 -4.125
201512 -3.600 99.792 -4.669
201603 -7.400 100.470 -9.532
201606 -6.600 101.688 -8.400
201609 -9.400 101.861 -11.943
201612 -6.000 101.863 -7.623
201703 -3.600 102.862 -4.529
201706 -6.400 103.349 -8.014
201709 -7.400 104.136 -9.197
201712 -7.000 104.011 -8.710
201803 -10.600 105.290 -13.029
201806 -4.800 106.317 -5.843
201809 -5.800 106.507 -7.048
201812 -8.000 105.998 -9.768
201903 2.400 107.251 2.896
201906 -7.600 108.070 -9.101
201909 -6.600 108.329 -7.885
201912 -4.400 108.420 -5.252
202003 -6.200 108.902 -7.368
202006 -5.600 108.767 -6.663
202009 -5.600 109.815 -6.600
202012 -3.600 109.897 -4.240
202103 -5.400 111.754 -6.254
202106 -7.400 114.631 -8.355
202109 14.400 115.734 16.103
202112 -6.000 117.630 -6.601
202203 -3.800 121.301 -4.054
202206 -3.400 125.017 -3.520
202209 -3.800 125.227 -3.927
202212 -4.800 125.222 -4.961
202303 -4.400 127.348 -4.472
202306 -4.000 128.729 -4.021
202309 -3.200 129.860 -3.189
202312 -2.400 129.419 -2.400

Add all the adjusted EPS together and divide 10 will get our e10.


Agenus  (NAS:AGEN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Agenus E10 Related Terms

Thank you for viewing the detailed overview of Agenus's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (Agenus) Business Description

Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Executives
Ulf Wiinberg director
Steven J O'day officer: Chief Medical Officer 2344 BANYAN DRIVE, LOS ANGELES CA 90049
Garo H Armen officer: Chairman & CEO 3 FORBES ROAD, LEXINGTON MA 02421
Christine M Klaskin officer: VP Finance 3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss officer: Chief Legal Officer 139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch director 280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp 10 percent owner 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan officer: Chief Technology Officer 3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns officer: V.P. and General Counsel AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell officer: Chief Operating Officer 3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis director FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan director ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010